Inactivation of severe acute respiratory syndrome coronavirus 2 in plasma and platelet products using a riboflavin and ultraviolet light‐based photochemical treatment

• Published in: Vox sanguinis Vol. 115; no. 6; pp. 495 - 501
• Main Authors: Keil, Shawn D., Ragan, Izabela, Yonemura, Susan, Hartson, Lindsay, Dart, Nicole K., Bowen, Richard
• Format: Journal Article
• Language: English
• Published: England S. Karger AG 01.08.2020; John Wiley and Sons Inc
• Subjects: Animals; Betacoronavirus - drug effects; Betacoronavirus - radiation effects; Blood; Blood platelets; Blood Platelets - virology; Blood Safety - methods; Blood-Borne Pathogens - drug effects; Blood-Borne Pathogens - radiation effects; Cell culture; Chlorocebus aethiops; Coronaviridae; Coronaviruses; COVID-19; Deactivation; Disease transmission; Health services; Humans; Inactivation; Light; Original Paper; Pandemics; pathogen reduction; Pathogens; Photochemicals; Photosensitizing Agents - pharmacology; Plaque assay; Plasma; Plasma - virology; Platelets; Respiratory diseases; Respiratory distress syndrome; Riboflavin; Riboflavin - pharmacology; Ribonucleic acid; RNA; SARS-CoV-2; Severe acute respiratory syndrome; Severe acute respiratory syndrome coronavirus 2; Tissue culture; Transfusion; Transfusion‐transmitted Disease and its Prevention; ultraviolet; Ultraviolet radiation; Ultraviolet Rays; Vero Cells; Viral diseases; Viruses; Vitamin B; COVID-19; SARS-CoV-2; blood; ultraviolet; riboflavin; pathogen reduction

Background and Objective Severe acute respiratory distress syndrome coronavirus‐2 (SARS‐CoV‐2), the causative agent of coronavirus disease 2019 (COVID‐19), is a member of the coronavirus family. Coronavirus infections in humans are typically associated with respiratory illnesses; however, viral RNA...